Regulatory approvals in Slovakia and Egypt

Eden Research plc

04 August 2026

4 August 2026

Eden Research plc

("Eden" or the "Company")

Regulatory approvals in Slovakia and Egypt

Eden extends its European footprint and secures its first authorisation for Mevalone® in North Africa

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, announces it has received regulatory authorisation for its Botrytis (grey mould) fungicide in two further territories: Slovakia, where the product has been registered as Mevalone®, and Egypt, where it has been registered by Eden's commercial partner as Trilogy™.

Key highlights for these approvals are:

Slovakia

-      authorised for use on grapes and pome fruits from July 2026

-      commercialised by Biocont in Slovakia

-      addresses Botrytis in an important wine-producing market

-      strengthens Eden's position in Central Europe's growing biological crop protection market

Egypt

-      approved for use on grapes with no pre-harvest interval

-      commercialised by Sipcam Inagra Egypt

-      strong advantage for Egypt's major table grape export industry by supporting last-minute disease control

-      First Mevalone® registration in North Africa with further approvals being pursued in the region

Slovakia

The Slovak authorisation for use on grapes and pome fruit was granted in July by the Central Control and Testing Institute of Agriculture (ÚKSÚP). The product will be commercialised in Slovakia by Biocont, Eden's distribution partner in a number of central European countries, a leading specialist in biological and integrated crop protection solutions for the region's fruit and viticulture growers.

Slovakia has six designated wine-growing regions covering approximately 14,400 hectares of vineyard, producing around 332,000 hectolitres of wine annually and some 51,700 tonnes of wine grapes in 2025. Botrytis cinerea is the principal late-season disease pressure in the region, and Slovak vineyards are subject to the same tightening of conventional active substances as the rest of the EU, driving greater demand for residue-free biological alternatives. The approval strengthens both Eden's and Biocont's market position in Slovakia and supports their broader expansion of sustainable crop protection across the region.

Egypt

In Egypt, registration has been granted for use in grapes against Botrytis cinerea with no pre-harvest interval required. Registration was secured and will be commercialised by the Sipcam Oxon, Eden's shareholder and long-standing partner in Southern Europe and North Africa, through Sipcam Inagra S.A. and its subsidiary Sipcam Inagra Egypt.  Eden and Sipcam continue to pursue registrations for the same product in Algeria, Tunisia and Morocco.

Egypt is one of the world's largest table grape producers and a significant exporter, with commercial table grape production of approximately 1.59 million tonnes in the 2024/25 marketing year, second only to citrus among Egyptian fruit crops. Grapes are grown from Alexandria in the north to Aswan in the south, giving an unusually long marketing window from May to November, and the European Union remains the principal destination for Egyptian exports. Because EU-bound fruit is subject to strict maximum residue limit and retailer requirements, the absence of a pre-harvest interval is a material commercial advantage: growers can apply the product immediately before harvest which translates into reduced crop loss due to disease-related damage. This is the first authorisation for Mevalone® in the important and growing North African region, a key supplier of fresh fruits and vegetables to European and local consumers, alike.

Sean Smith, Chief Executive Officer of Eden Research, commented: "These two represent important commercial milestones. Slovakia expands our European footprint through Biocont's established grower network and where the transition away from conventional chemistry is well underway. Our partnership with Biocont simplifies the value chain and helps both partners deliver greater value to growers. 

"Egypt marks the first authorisation in North Africa for Mevalone® and with no pre-harvest interval on the label, it provides a strong advantage for growers supplying highly regulated export markets. I would like to thank our partners at Biocont and Sipcam, and our own regulatory team, whose work over several years has delivered both of these registrations. We continue to work with Sipcam on the neighbouring markets of Algeria, Tunisia and Morocco and look forward to further regional expansion."

For further information contact:

Eden Research plc		www.edenresearch.com
Sean Smith, Chief Executive Officer		Via Walbrook PR
Alex Abrey, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated advisor and joint broker)		Tel: 020 7220 0500
Giles Balleny / Elysia Bough (Corporate Finance)
Harriet Ward (Corporate Broking) / Dale Bellis (Sales)
Oberon Capital (Joint Broker)		Tel: 020 3179 5300
Nick Lovering / Mike Seabrook / Adam Pollock
Walbrook PR (Media Relations & Investor Relations)	Tel: 020 7933 8780 or eden@walbrookpr.com
Paul McManus / Nick Rome / Anna Dunphy

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, Mevalone®is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz™is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product (approval expected in 2026), Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

Eden's Sustaine^® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit:  www.edenresearch.com.

Follow Eden on LinkedIn, Twitter and YouTube. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.